The role of GDF-15 in heart failure patients with chronic kidney disease
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00077846" target="_blank" >RIV/00023001:_____/19:00077846 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/19:43917906 RIV/00064190:_____/19:N0000065
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S0828282X18313898?token=659ED51CEF7E79A092B69308852E0D3042A10B061D23D114D181B8CDC81139BBAE9B90DF27A4E2FE1AAF13B5B76C403C" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0828282X18313898?token=659ED51CEF7E79A092B69308852E0D3042A10B061D23D114D181B8CDC81139BBAE9B90DF27A4E2FE1AAF13B5B76C403C</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.cjca.2018.12.027" target="_blank" >10.1016/j.cjca.2018.12.027</a>
Alternative languages
Result language
angličtina
Original language name
The role of GDF-15 in heart failure patients with chronic kidney disease
Original language description
Background: Growth differentiation factor-15 (GDF-15) is a stressinducible cytokine and member of the transforming growth factor-b cytokine superfamily that refines prognostic assessment in subgroups of patients with heart failure (HF). We evaluated its role in HF patients with chronic kidney disease (CKD, estimated glomerular filtration rate < 60 mL/min/1.73 m(2)). Methods: A total of 358 patients with stable systolic HF were followed for a median of 1121 (interquartile range, 379-2600) days. Comprehensive evaluation including B-type natriuretic peptide (BNP) and GDF15 testing was performed at study entry; the analysis was stratified according to kidney function. Results: Patients with CKD (33.8%) were older, had more often diabetes, and were less often treated with angiotensin converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB). GDF-15 was associated with estimated glomerular filtration rate, whereas BNP was associated with left ventricular-end diastolic diameter and ejection fraction (P < 0.01). During follow-up, 244 patients (68.2%) experienced an adverse outcome 9death, urgent transplantation, implantation of mechanical circulatory support). In patients with HF and CKD, the Cox proportional hazard model identified BNP, GDF-15, sex, systolic blood pressure, sodium, total cholesterol, and ACEi/ARB treatment as significant variables associated with an adverse outcome 9P < 0.05). In multivariable analysis, BNP was replaced by GDF-15. Net reclassification improvement confirmed prognostic superiority of the model encompassing GDF-15 9GDF-15, sodium, total cholesterol, ACEi/ARB treatment) compared with the model without GDF-15 9BNP, sex, sodium, ACEi/ARB treatment), net reclassification improvement 0.62, P = 0.005. In contrast, in patients with HF and normal kidney function, BNP remained superior to GDF-15 in a multivariable model. Conclusions: In patients with systolic HF and CKD, GDF-15 is more strongly associated with adverse outcomes than the conventionally used BNP.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Canadian journal of cardiology
ISSN
0828-282X
e-ISSN
—
Volume of the periodical
35
Issue of the periodical within the volume
4
Country of publishing house
CA - CANADA
Number of pages
9
Pages from-to
462-470
UT code for WoS article
000462763000017
EID of the result in the Scopus database
2-s2.0-85063501937